Ein wichtiger Marker für die Entwicklung von Diabetes wurde identifiziert.
Die beiden wichtigen Hormone, die in der Bauchspeicheldrüse produziert werden – Glucagon und Insulin – richtig kontrollieren Glucose als Reaktion auf die Nahrung, die wir konsumieren. Glucagon erhöht die hepatische Glukoseproduktion (HGP) und Insulin senkt sie. Beide kontrollieren die Blutzuckerhomöostase. Wenn wir fasten, wird Glucagon von den A-Zellen der Bauchspeicheldrüse ausgeschüttet, um den Blutzuckerspiegel im Körper zu erhöhen, um den Körper vor einer sogenannten Hypoglykämie zu schützen, bei der der Blutzuckerspiegel einer Person drastisch sinkt und zu Symptomen führt. Glucagon ist an der Entwicklung einer diabetischen Hyperglykämie beteiligt, wenn die hepatische Glukoseproduktion (HGP) erhöht ist. Insulin unterdrückt die Glukoseproduktion durch transkriptionelles reguläres In Leber cells. A protein called Transcription factor Foxo1 plays an important role in regulating expression of genes and promoting HGP by increasing expression of genes which are responsible for production of glucose. Disruption of proper HGP is understood as a key primary mechanism for development of Type 2 Diabetes.
In einer Studie, die in Diabetes, researchers from Texas A&M University USA set out to understand the role of Foxo1 in how glucagon regulates HGP. They wanted to better understand the fundamentals of blood glucose homeostasis and pathogenesis of diabetes. Glucagon does its function by binding to a GPCR receptor, stimulating the cell membrane to activate protein kinase A which then signals gene expression to increase blood glucose. The levels of glucagon are extremely high in humans with Diabetes and this stimulates excess production of HGP.
Researchers investigated Foxo1 regulation through phosphorylation i.e. attachment of a phosphoryl group. Phosphorylation is an important part of protein function and is responsible for activating or deactivating almost 50 percent of enzymes present in our body, and thereby regulating their function. Researchers used mice model and gene editing to generate Foxo1 ‘knock in’ mice. Foxo1 was stabilised in Leber of mice (who were fasting) when insulin was decreased and glucagon increased in the bloodstream. The study clearly showed that if hepatic Foxo1 was deleted, hepatic glucose production (HGP) and blood glucose was decreased in mice. Thus, a novel mechanism has been identified for the first time in which Foxo1 mediates glycogen signalling via phosphorylation in order to control blood glucose.
Foxo1 is an important protein that acts as a mediator for various pathways integrating hormones and other proteins to control insulin sensitivity. Since high glucagon levels are present both in Type 1 and Type 2 Diabetes, Foxo1 will play an important role in the fundamental mechanism leading to diabetic hyperglycaemia. The study suggests that glucagon mediated HGP can be a potential therapeutic intervention for control and also possible prevention of Diabetes.
***
{Sie können das ursprüngliche Forschungspapier lesen, indem Sie auf den unten angegebenen DOI-Link in der Liste der zitierten Quellen klicken}
Quelle (n)
YuxinW et al. 2018. Neuer Mechanismus der Foxo1-Phosphorylierung bei der Glucagon-Signalgebung bei der Kontrolle der Glukosehomöostase.Diabetes. 67(11). https://doi.org/10.2337/db18-0674
***
